Statement on aducanumab and Biogen decision

The Alzheimer Society of Canada has been made aware of the decision by Biogen Canada Inc. to withdraw its submission of aducanumab from regulatory review by Health Canada as a treatment for people living with early stages of Alzheimer’s disease.

“This decision will disappoint many people who had experienced positive responses to trials of the treatment, as well as those who had watched with interest and supported its approval for use in Canada.

The Alzheimer Society of Canada respects the decision made by Biogen and renews its call for additional funding for dementia research. Canada’s per capita funding commitments are far behind the funds allocated for cancer and heart disease and we rank well behind several of our G7 peers.

This must change so that new breakthroughs can be developed, tested and approved to provide hope for people living with dementia.”